North American Scientific Introduces BATCAM Multi-Probe Ultrasound Image Guided Radiation Therapy Solution
23 Julio 2007 - 7:00AM
Business Wire
North American Scientific, Inc. (Nasdaq:NASI) announced today that
its NOMOS Radiation Oncology division will introduce BATCAM�
Multi-probe, its new IGRT solution, at the upcoming 49th Annual
Meeting of the American Association of Physics in Medicine (AAPM).
BATCAM Multi-probe received FDA 510(k) approval on July 11, 2007.
AAPM will be held in Minneapolis, MN, July 22-26, 2007, and the
NOMOS Radiation Oncology division will be presenting at Booth No.
529. North American Scientific will be presenting its ClearPath�
multi-channel catheter breast brachytherapy devices, Prospera�
brachytherapy seeds and SurTRAK� needles and strands in Booth No.
1147. BATCAM Multi-probe integrates a new multi-probe capable
ultrasound system into the company's core IGRT product, BATCAM. The
new system features an updated abdominal ultrasound probe featuring
color doppler ultrasound enabling IGRT for liver and pancreas
treatments in addition to prostate and gynecology. Optional add-ons
to the system include a bi-planar rectal probe for prostate volume
studies and prostate brachytherapy, and a wideband, linear probe
for verification of Accelerated Partial Breast Irradiation (APBI)
brachytherapy devices such as ClearPath�. BATCAM Multi-probe is
expected to be available for shipment in early August. "BATCAM
Multi-probe is a crucial advancement in providing improved imaging
and value to clinicians seeking IGRT solutions and offers greater
utility in addition to expanded clinical IGRT use,� said John Rush,
President and Chief Executive Officer of North American Scientific.
�Facilities that adopt this new technology will quickly realize the
benefits of a system that can be applied to a wide variety of
applications throughout their cancer clinic. We are particularly
pleased to present a product that is equipped to provide support
for our brachytherapy business, including our Prospera�
brachytherapy seeds and the ClearPath� devices which we plan to
launch commercially later this year." About North American
Scientific North American Scientific is a leader in radiation
therapy products and services in the fight against cancer. Its
innovative products provide physicians with tools for the treatment
of various types of cancers. They include Prospera� brachytherapy
seeds and SurTRAK� needles and strands used primarily in the
treatment of prostate cancer. In addition the Company plans to
commercialize its ClearPath� multi-channel catheter breast
brachytherapy devices in 2007, which are the only devices approved
for both high dose and continuous release, or low dose, radiation
treatments. The devices are designed to provide flexible, precise
dose conformance and an innovative delivery system that is intended
to offer the more advanced form of brachytherapy for the treatment
of breast cancer. North American Scientific�s NOMOS� Radiation
Oncology Division provides external beam radiation therapy products
for Serial Tomotherapy Intensity Modulated Radiation Therapy (IMRT)
and Image-Guided Radiation Therapy (IGRT). Serial tomotherapy IMRT
allows an escalated radiation dose to be delivered to a tumor while
limiting exposure and damage to nearby healthy tissue. These
products are marketed under the trade names nomosSTAT�and CORVUS�
(our proprietary treatment planning software). The Company's IGRT
products, BAT�, BATCAM� and nTRAK�, provide fast and accurate
targeting and localization of a treatment volume on a daily basis.
More than 500 hospitals and research sites worldwide are equipped
with the Company's clinically proven serial tomotherapy, inverse
treatment planning, image-guidance and ancillary treatment
solutions. Please visit www.nasmedical.com for more information.
Statements included in this release that are not historical facts
may be considered forward-looking statements that are subject to a
variety of risks and uncertainties. There are a number of important
factors that could cause actual results to differ materially from
those expressed in any forward-looking statements made by the
Company including, but not limited to, the impact of competitive
products and pricing, technological changes, changes in
relationships with strategic partners and dependence upon strategic
partners for the performance of critical activities under
collaborative agreements, the ability of the Company to
successfully directly market and sell its products, uncertainties
relating to patent protection and regulatory approval, the stable
supply of appropriate isotopes, research and development estimates,
market opportunities, risks associated with strategic opportunities
or acquisitions the Company may pursue and the risk factors
included in the Company's filings with the Securities and Exchange
Commission. Any forward-looking statements contained in this news
release speak only as of the date of this release, and the Company
undertakes no obligation to revise or update any forward-looking
statements, whether as a result of new information, future results
or otherwise.
North American Scientific (MM) (NASDAQ:NASI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
North American Scientific (MM) (NASDAQ:NASI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about North American Scientific (MM) (NASDAQ): 0 recent articles
Más de North American Scientific, Inc. ArtÃculos de Noticias